+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID06943755

Randomized Study Comparing Zanzalintinib and Everolimus for Advanced or Metastatic Neuroendocrine Tumors

Led by Exelixis · Updated on 2026-10-30

440

Participants Needed

135

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced, or metastatic neuroendocrine tumors. This Phase 23, randomized, open-label study focuses on participants with well-differentiated Grade 1, 2, or 3 neuroendocrine tumors of pancreatic or extra-pancreatic origin who have experienced disease progression after prior therapies. Participants will be randomly assigned to receive either zanzalintinib or everolimus as oral tablets taken once daily. The study uses a crossover design, allowing participants to switch treatments during the trial. Tumor tissue samples are collected if available, and imaging assessments using CT or MRI scans will be performed to evaluate disease status. During the study, participants will be closely monitored for progression-free survival up to 48 months, along with secondary outcomes including overall survival, response rates, and quality of life measures. Safety is assessed by tracking adverse events over the trial period. Participants are expected to attend regular visits for assessments and evaluations throughout the duration of the study, which is planned to continue until June 2029.

CONDITIONS

Brief Title

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Research Team

E

Exelixis Clinical Trials

B

Backup or International

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here